next announcement and likely content, page-93

PLasticd, a very sensible post. Glad you could decipher mine… my speed typing is getting better but me accuracy goes out the window.

ANPs aim is to a do preclinical development/R&D etc of antisense and to outsource the rest/later stages or clinical trials… similar to what ISIS does it is on the ANP website. I realise the lengthy times involved for approvals/trails etc regarding retinopathy. Maybe to outsource early would see them able to work on their other drugs or take on something more off of ISIS.

I believe there is more work to be done with ATL1102…. ATL1102 is for MS, Asthma and stem cell mobilization yet they only licence the application of MS to Teva… as we know teva plonked… there is still much value to be has out of this drug yet imo. What do you think of the stem cell mobilization indications? Also you mentioned science… are you a scientist?

ATL1101 I believe we may hear more about over the next week or so (just a hunch)

Regarding capital, they did state no CR for 2011 so we should be free to run right up to results. further CR (if needed) I believe would be done to a pharmaceutical co or ISIS themselves IMHO.

I notice ANP did vote with the substantial shareholders shares at the AGM…some 250 million votes so they have these guys on side!!

As you say when a new generation of drugs hits the market it is big new and sees massive capital and investment flow in to all involved…. Lucky old ANP holding the holy grail of the bunch gen2 liver.

It will be a big wave to ride so good to be on for the long haul!


Good Luck!